FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Kjersem, Janne B ^a   Skovlund, Eva ^b   Ikdahl, Tone ^a   Guren, Tormod ^a   Kersten, Christian ^c   Dalsgaard, Astrid M ^a   Yilmaz, Mette K ^d   Fokstuen, Tone ^e   Tveit, Kjell M ^a   Kure, Elin H ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c Southern Hospital Trust   (Norway)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cetuximab; Colorectal cancer; FCGR2A; FCGR3A; Polymorphism

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; FC RECEPTOR; FCGR2A PROTEIN, HUMAN; FCGR3A PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ADULT; AGED; ARTICLE; CODON; CONTROLLED STUDY; DRUG RESPONSE; FCGR2A GENE; FCGR3A GENE; FEMALE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TIME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTORS, IGG; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901818196     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-340     Document Type: Article

References (39)

1. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B. Colorectal cancer. Lancet 2010, 375:1030-1047. 10.1016/S0140-6736(10)60353-4, 20304247.
2. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010, 32:437-453. 10.1016/j.clinthera.2010.03.012, 20399983.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765. 10.1056/NEJMoa0804385, 18946061.
4. Lievre A, Bachet JB, Boige V, Cayre A, Le CD, Buc E. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379. 10.1200/JCO.2007.12.5906, 18202412.
5. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012, 30:1755-1762. 10.1200/JCO.2011.38.0915, 22473155.
6. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114. 10.1016/S0140-6736(11)60613-2, 3159415, 21641636.
7. Primrose JN, Falk S, Finch-Jones M, Valle JW, Sherlock D, Hornbuckle J. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: the new EPOC study. ASCO Meeting Abstracts 2013, 31:3504.
8. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007, 13:1552-1561. 10.1158/1078-0432.CCR-06-1726, 17332301.
9. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 2007, 12:898-910. 10.1016/j.drudis.2007.08.009, 17993407.
10. van Sorge NM, van der Pol WL, van de Winkel JG. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003, 61:189-202. 10.1034/j.1399-0039.2003.00037.x, 12694568.
11. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947. 10.1200/JCO.2003.05.013, 12975461.
12. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758. 10.1182/blood.V99.3.754, 11806974.
13. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796. 10.1200/JCO.2007.14.8957, 18347005.
14. Tamura K, Shimizu C, Hojo T, Kashi-Tanaka S, Kinoshita T, Yonemori K. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011, 22:1302-1307. 10.1093/annonc/mdq585, 21109570.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
16. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes RF, Barugel MF. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013, 369:1023-1034. 10.1056/NEJMoa1305275, 24024839.
17. Seymour MT, Brown SR, Middleton G, Maughan TF, Richman S, Gwyther S, Lowe C. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013, 14:749-759. 10.1016/S1470-2045(13)70163-3, 3699713, 23725851.
18. De RW, Claes B, Bernasconi D, De SJ, Biesmans B, Fountzilas G. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762. 10.1016/S1470-2045(10)70130-3, 20619739.
19. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009, 169:505-514. 2640163, 19126586.
20. Paez D, Pare L, Espinosa I, Salazar J, Del RE, Barnadas A. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?. Cancer Sci 2010, 101:2048-2053. 10.1111/j.1349-7006.2010.01621.x, 20550522.
21. Zhang W, Yang D, Harbison C, Khambata-Ford S, Malone DP, Ning Y. FCGR2A H131R and FCGR3A V158F polymorphism status in mCRC patients treated with single-agent cetuximab (IMCL 0144 and CA225045) or with second-line irinotecan plus cetuximab (EPIC): a pooled statistical analysis. ASCO Meeting Abstracts 2011, 29:e14025.
22. Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics J 2013, 14:14-19.
23. Bibeau F, Lopez-Crapez E, Di FF, Thezenas S, Ychou M, Blanchard F. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009, 27:1122-1129. 10.1200/JCO.2008.18.0463, 19164213.
24. Rodriguez J, Zarate R, Bandres E, Boni V, Hernandez A, Sola JJ. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur J Cancer 2012, 48:1774-1780. 10.1016/j.ejca.2012.01.007, 22305465.
25. Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I. Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. Br J Clin Pharmacol 2012, 73:776-785. 10.1111/j.1365-2125.2011.04141.x, 3403205, 22486600.
26. Calemma R, Ottaiano A, Trotta AM, Nasti G, Romano C, Napolitano M. Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. J Transl Med 2012, 10:232. 10.1186/1479-5876-10-232, 3551834, 23171437.
27. Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res 2010, 30:4209-4217.
28. Dahan L, Norguet E, Etienne-Grimaldi MC, Formento JL, Gasmi M, Nanni I. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer 2011, 11:496. 10.1186/1471-2407-11-496, 3235081, 22117530.
29. Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der ST. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010, 46:1829-1834. 10.1016/j.ejca.2010.03.017, 20418097.
30. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007, 25:3712-3718. 10.1200/JCO.2006.08.8021, 17704420.
31. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 2008, 14:7884-7895. 10.1158/1078-0432.CCR-07-5165, 19047118.
32. Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008, 26:1427-1434. 10.1200/JCO.2007.12.4602, 18349392.
33. Park SJ, Hong YS, Lee JL, Ryu MH, Chang HM, Kim KP. Genetic polymorphisms of FcgammaRIIa and FcgammaRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer. Oncology 2012, 82:83-89. 10.1159/000335959, 22327884.
34. Geva R, Jensen BV, Fountzilas G, Yoshino T, Paez D, Montagut C. An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy. ASCO Meeting Abstracts 2011, 29:3528.
35. Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer 2010, 46:1703-1711. 10.1016/j.ejca.2010.03.005, 20399639.
36. Schlaeth M, Berger S, Derer S, Klausz K, Lohse S, Dechant M. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Cancer Sci 2010, 101:1080-1088. 10.1111/j.1349-7006.2010.01505.x, 20331636.
37. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000, 6:443-446. 10.1038/74704, 10742152.
38. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 2002, 62:5813-5817.
39. de Souza AP, Bonorino C. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther 2009, 9:1317-1332. 10.1586/era.09.88, 19761435.